Clinical trial
Gefitinib in Treating Patients With Cervical Cancer
NCT00049556 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00049556 |
|---|---|
| Title | Gefitinib in Treating Patients With Cervical Cancer |
| Official title | Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or Cervical Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug, Other, Procedure |
| Interventions | gefitinib, immunohistochemistry staining method, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy, sentinel lymph node biopsy |
| Start date | Oct 1, 2002 |
| Completion | Aug 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: